The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of ATI-1123, a novel human serum albumin-stabilized docetaxel liposomal formulation, in patients with advanced solid malignancies.
S. Vemulapalli
No relevant relationships to disclose
A. C. Mita
No relevant relationships to disclose
N. S. Gallegos
Employment or Leadership Position - Azaya Therapeutics
G. Anderson
Employment or Leadership Position - Azaya Therapeutics
J. Charles
Employment or Leadership Position - Azaya Therapeutics
J. M. Rogers
No relevant relationships to disclose
A. Kousba
No relevant relationships to disclose
K. K. Sankhala
No relevant relationships to disclose
J. J. Nemunaitis
No relevant relationships to disclose